Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up


KARAKAYA M. F. , özer s., Kalkan C., Tuzun E. A. , Caliskan A., Keskin O. , ...Daha Fazla

ANTIVIRAL THERAPY, cilt.22, ss.559-570, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 22 Konu: 7
  • Basım Tarihi: 2017
  • Doi Numarası: 10.3851/imp3144
  • Dergi Adı: ANTIVIRAL THERAPY
  • Sayfa Sayıları: ss.559-570

Özet

Background: Finite treatment of hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) with nucleoside/nucleotide analogues (NAs) is important in resource-limited countries. Outcome of treatment discontinuation in patients on long-term lamivudine (LVD) was assessed in a single centre observational pilot study in the current study.